近期,国内多家药企公布创新药研发III期临床进展,涉及多个治疗领域。康哲药业9月28日宣布,旗下德镁医药的1类新药抗IL-4Rα MG-K10人源化单抗注射液获NMPA批准,将开展用于慢性自发性荨麻疹的III期临床试验,MG-K10具有更长半衰期,有望成为全球首个长效抗IL-4Rα单抗。9月26日,第一三共宣布Ifinatamab Deruxtecan用于二线治疗晚期/转移性食管鳞癌的III期研究...
Source Link近期,国内多家药企公布创新药研发III期临床进展,涉及多个治疗领域。康哲药业9月28日宣布,旗下德镁医药的1类新药抗IL-4Rα MG-K10人源化单抗注射液获NMPA批准,将开展用于慢性自发性荨麻疹的III期临床试验,MG-K10具有更长半衰期,有望成为全球首个长效抗IL-4Rα单抗。9月26日,第一三共宣布Ifinatamab Deruxtecan用于二线治疗晚期/转移性食管鳞癌的III期研究...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.